Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $17.43 to $18.50
• 50-Day Range: $12.53 to $18.23
• 52-Week Range: $8.89 to $24.50
• Volume: 343,873 shs
• Average Volume: 530,013 shs
• Market Capitalization: $796.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.56
• Consensus Rating: Moderate Buy

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 at the beginning of the year. Since then, BBNX stock has decreased by 23.0% and is now trading at $18.33.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) released its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.12. The company earned $23.24 million during the quarter, compared to analysts' expectations of $19.73 million.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an IPO on Thursday, January 30th 2025. The company issued 12,000,000 shares at $17.00 per share.

When did the company's lock-up period expire?

Beta Bionics's lock-up period expired on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Beta Bionics' major shareholders?

Beta Bionics' top institutional investors include Eventide Asset Management LLC (11.35%), Soleus Capital Management L.P. (8.79%), Sands Capital Alternatives LLC (8.21%) and Divisadero Street Capital Management LP (2.18%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider and Mark Hopman.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Beta Bionics: $22.56
• High Price Target: $30.00
• Low Price Target: $16.00
• Potential Upside/Downside: +29.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.68
• Quick Ratio: 13.79

Sales & Book Value

• Annual Sales: $78.02 million
• Price / Sales: 9.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.72) per share
• Price / Book: -3.05

Miscellaneous

• Outstanding Shares: 43,470,000
• Free Float: N/A
• Market Cap: $758.55 million
• Optionable: N/A
• Beta: N/A